Physician profile
Raphael X Ye
NPI 1326314584
$13,391.23
in general payments reported to CMS, 2019-2025
30 companies · $52.90 in 2025
The $52.90 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,172 · 2020: $1,870 · 2021: $4,105 · 2022: $3,875 · 2023: $966 · 2024: $351 · 2025: $52.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,759.12 | 2019-2025 | Proclaim, Eterna, Octrode |
| Collegium Pharmaceutical, INC. | $312.82 | 2019-2023 | Belbuca |
| Biohaven Pharmaceuticals, INC. | $261.09 | 2020-2021 | |
| Abbvie INC. | $251.59 | 2021-2024 | |
| Zyla Life Sciences, INC. | $246.16 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.58 | 2022 | |
| Biodelivery Sciences International, INC. | $143.28 | 2019-2021 | |
| Boston Scientific Corporation | $139.24 | 2020 | |
| Medtronic USA, INC. | $119.99 | 2020 | |
| Saluda Medical Americas, INC. | $118.32 | 2023 | Evoke Scs |
| Pfizer INC. | $111.26 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $76.25 | 2019-2021 | |
| Amgen INC. | $69.04 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $61.46 | 2019-2022 | |
| Lilly USA, LLC | $61.43 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $59.76 | 2019-2021 | |
| Allergan, INC. | $54.63 | 2020 | |
| Grt US Holding, INC. | $54.20 | 2020-2021 | |
| Ibsa Pharma INC. | $50.69 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.16 | 2020-2021 | |
| Medtronic, INC. | $39.24 | 2022 | |
| Fidia Pharma USA INC. | $37.10 | 2025 | Hymovis, Triluron |
| Arbor Pharmaceuticals, INC. | $29.36 | 2019-2021 | |
| Daiichi Sankyo INC. | $24.65 | 2019 | |
| Horizon Therapeutics Plc | $24.57 | 2020 | |
| Foundation Fusion Solutions, LLC | $20.11 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.24 | 2022 | |
| Spinal Simplicity, LLC | $19.07 | 2024 | Ha Minuteman G3-R |
| Mdd US Operations, LLC | $14.04 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.